These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
45. Analysis and purification of human lymphoblastoid (Namalwa) interferon using a monoclonal antibody. Allen G; Fantes KH; Burke DC; Morser J J Gen Virol; 1982 Nov; 63 (Pt 1)():207-12. PubMed ID: 7175502 [TBL] [Abstract][Full Text] [Related]
46. Biological similarities of rat fibroblast interferon to human and mouse alpha interferons. Davis CT; Rusckowski M; Murasko DM J Gen Virol; 1985 Sep; 66 ( Pt 9)():1961-8. PubMed ID: 2411850 [TBL] [Abstract][Full Text] [Related]
47. [Method of increasing the activity of a preparation of human cadaver leukocyte interferon]. Parfenov VV; Zubanova NA; Mekhedov LN; Pokidysheva LN; Kuznetsov VP Vopr Virusol; 1980; (3):294-7. PubMed ID: 6159731 [TBL] [Abstract][Full Text] [Related]
48. The kinetics of human interferon clearance in gibbons. Skreko F; Zajac I; Bahnsen HP; Haff RF; Cantell K Proc Soc Exp Biol Med; 1973 Mar; 142(3):946-7. PubMed ID: 4692028 [No Abstract] [Full Text] [Related]
49. Purification of interferon by adsorption chromatography on controlled pore glass. Edy VG; Braude IA; De Clercq E; Billiau A; De Somer P J Gen Virol; 1976 Dec; 33(3):517-21. PubMed ID: 1036458 [TBL] [Abstract][Full Text] [Related]
50. Production of human leukocyte interferon for clinical use under immunoelectrophoretic control. Fuchsberger N; Borecký L Acta Biol Med Ger; 1979; 38(5-6):795-800. PubMed ID: 230675 [TBL] [Abstract][Full Text] [Related]
51. Physico-chemical characterization and partial purification of mouse immune interferon. Wietzerbin J; Stefanos S; Lucero M; Falcoff E; O'Malley JA; Sulkowski E J Gen Virol; 1979 Sep; 44(3):773-81. PubMed ID: 43358 [TBL] [Abstract][Full Text] [Related]
52. [Clinical trials of recombinant gamma-interferon. Circulating interferon and the 2,5-oligoadenylate synthetase activity after intramuscular and inhalation administrations]. Sokolova TM; Lopatina OA; Nosik NN; Cheshik SG Biull Eksp Biol Med; 1993 Jun; 115(6):633-4. PubMed ID: 7690616 [TBL] [Abstract][Full Text] [Related]
53. Tolerability of pure fibroblast interferon in man. Billiau A; Heine JW; Van Damme J; Heremans H; De Somer P Ann N Y Acad Sci; 1980; 350():374-5. PubMed ID: 6165288 [No Abstract] [Full Text] [Related]
54. Production and preparation of human fibroblast interferon for clinical trials. Leong SS; Horoszewicz JS Methods Enzymol; 1981; 78(Pt A):87-101. PubMed ID: 6173652 [No Abstract] [Full Text] [Related]
55. Lethality of interferon preparations for newborn mice. Gresser I; Tovey MG; Maury C; Chouroulinkov I Nature; 1975 Nov; 258(5530):76-8. PubMed ID: 1186883 [No Abstract] [Full Text] [Related]
56. Toxicity of interferon. Fumarola D Br Med J (Clin Res Ed); 1981 Nov; 283(6304):1468-9. PubMed ID: 6172179 [No Abstract] [Full Text] [Related]
58. Toxicity of interferon. Fumarola D Br Med J (Clin Res Ed); 1981 Jul; 283(6285):235. PubMed ID: 6167309 [No Abstract] [Full Text] [Related]
59. Targeting of Immune Cells by Dual TLR2/7 Ligands Suppresses Features of Allergic Th2 Immune Responses in Mice. Laiño J; Wangorsch A; Blanco F; Wolfheimer S; Krause M; Flaczyk A; Möller TM; Tsai M; Galli S; Vieths S; Toda M; Scheurer S; Schülke S J Immunol Res; 2017; 2017():7983217. PubMed ID: 29204451 [TBL] [Abstract][Full Text] [Related]
60. Risks and benefits of interferon-alpha in the treatment of hepatitis. Pardo M; Marriott E; Moliner MC; Quiroga JA; Carreño V Drug Saf; 1995 Nov; 13(5):304-16. PubMed ID: 8785018 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]